Advisory Services Network’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Advisory Services Network’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-253	Closed	-$7K	–	1185
2020 Q1	$7K	Buy	+253	New	+$8.72K	﹤0.01%	2319
2019 Q1	–	Sell	-58,897	Closed	-$1.37M	–	2525
2018 Q4	$1.37M	Sell	58,897 -70,229	-54%	-$1.92M	0.12%	230
2018 Q3	$4.46M	Buy	129,126 +4,917	+4%	+$166K	0.33%	63
2018 Q2	$4.13M	Buy	124,209 +16,291	+15%	+$535K	0.31%	68
2018 Q1	$3.54M	Sell	107,918 -439	-0.4%	-$14.3K	0.28%	74
2017 Q4	$3.08M	Buy	108,357 +21,118	+24%	+$591K	0.27%	75
2017 Q3	$2.54M	Buy	87,239 +2,363	+3%	+$61.1K	0.29%	73
2017 Q2	$2.04M	Buy	84,876 +19,757	+30%	+$443K	0.27%	92
2017 Q1	$1.51M	Buy	+65,119	New	+$1.38M	0.22%	105

Other funds holding BBC

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

FEM

Fulcrum Equity Management Plano, Texas $136M AUM 42.95% 1-Year Est. Return

NCM

Niemann Capital Management Stateline, Nevada $788K AUM 23.27% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Advisory Services Network's BBC Position: Q2 2020 in Review

Advisory Services Network sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q2 2020, closing a stake of 253 shares — an estimated $7K sold.

Advisory Services Network first reported a position in BBC in Q1 2017 and held it in 9 quarters. The position peaked at $4.46M in Q3 2018. 19 funds tracked by Wall St. Rank hold BBC as of Q2 2020.

Advisory Services Network reported no remaining Virtus Biotech Clinical Trials ETF position as of Q2 2020 after selling out during the quarter.
Advisory Services Network sold 253 Virtus Biotech Clinical Trials ETF shares in Q2 2020, an estimated $7K.
Advisory Services Network first reported a position in Virtus Biotech Clinical Trials ETF in Q1 2017 and held it in 9 quarters.
Advisory Services Network's Virtus Biotech Clinical Trials ETF position peaked at $4.46M in Q3 2018.
19 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q2 2020.

Based on Advisory Services Network's 13F filing for Q2 2020, filed 10 Aug 2020.